Gross Profit Trends Compared: Ascendis Pharma A/S vs Veracyte, Inc.

Biotech Giants' Gross Profit Growth: 2014-2023

__timestampAscendis Pharma A/SVeracyte, Inc.
Wednesday, January 1, 20141398300021584000
Thursday, January 1, 2015811800028006000
Friday, January 1, 2016460600039623000
Sunday, January 1, 2017153000043758000
Monday, January 1, 20181058100058930000
Tuesday, January 1, 20191337500083845000
Wednesday, January 1, 2020695300076028000
Friday, January 1, 20214255000145114000
Saturday, January 1, 202239037000194954000
Sunday, January 1, 2023222323000248148000
Monday, January 1, 2024319383000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Ascendis Pharma A/S vs Veracyte, Inc.

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Ascendis Pharma A/S and Veracyte, Inc. over the past decade. Ascendis Pharma A/S, a leader in endocrinology, saw its gross profit skyrocket by over 1,500% from 2014 to 2023, peaking at $222 million. Meanwhile, Veracyte, Inc., a pioneer in genomic diagnostics, experienced a robust growth of approximately 1,050%, reaching $248 million in 2023.

Key Insights

  • 2014-2018: Veracyte consistently outperformed Ascendis, with gross profits nearly doubling each year.
  • 2019-2023: Ascendis closed the gap, achieving a remarkable surge in 2023.

These trends highlight the dynamic nature of the biotech sector, where innovation and strategic investments drive financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025